Name | YF-2 |
Description | YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM , respectively |
In vitro | YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells, respectively. |
In vivo | YF-2, administered intraperitoneally at doses of 20 mg/kg (2 hours before an electric shock) or 5 mg/kg (30 minutes prior to the electric shock), effectively rescues the defect in contextual memory in mice. At a dosage of 20 mg/kg without the electric shock treatment, YF-2 exhibits no impact on contextual memory in mice. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : Insoluble DMSO : 125 mg/mL (290.12 mM)
|
Keywords | YF 2 | HATs | inhibit | HAT | Histone Acetyltransferase | YF2 | YF-2 | Inhibitor |
Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Acetaminophen | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | CNS-Penetrant Compound Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Hypertension Compound Library |